Zenas BioPharma, Inc. Common Stock (ZBIO) - Total Assets
Based on the latest financial reports, Zenas BioPharma, Inc. Common Stock (ZBIO) holds total assets worth $747.68 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Zenas BioPharma, Inc. Common Stock service its debt to assess how comfortably operating cash covers total debt obligations.
Zenas BioPharma, Inc. Common Stock - Total Assets Trend (2022–2025)
This chart illustrates how Zenas BioPharma, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Zenas BioPharma, Inc. Common Stock for net asset value and shareholders' equity analysis.
Zenas BioPharma, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Zenas BioPharma, Inc. Common Stock's total assets of $747.68 Million consist of 91.5% current assets and 8.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Zenas BioPharma, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Zenas BioPharma, Inc. Common Stock.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zenas BioPharma, Inc. Common Stock's current assets represent 91.5% of total assets in 2025, a decrease from 91.8% in 2022.
- Cash Position: Cash and equivalents constituted 28.8% of total assets in 2025, down from 90.1% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Zenas BioPharma, Inc. Common Stock Competitors by Total Assets
Key competitors of Zenas BioPharma, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $553.60 Million |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $260.53 Million |
Zenas BioPharma, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.94 | 6.47 | 2.64 |
| Quick Ratio | 11.94 | 6.47 | 2.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $669.00 Million | $268.68 Million | $42.48 Million |
Zenas BioPharma, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Zenas BioPharma, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.12 |
| Latest Market Cap to Assets Ratio | 4.73 |
| Asset Growth Rate (YoY) | 3.7% |
| Total Assets | $383.64 Million |
| Market Capitalization | $1.82 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Zenas BioPharma, Inc. Common Stock's assets at a significant premium (4.73x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Zenas BioPharma, Inc. Common Stock's assets grew by 3.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Zenas BioPharma, Inc. Common Stock (2022–2025)
The table below shows the annual total assets of Zenas BioPharma, Inc. Common Stock from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $383.64 Million | +3.70% |
| 2024-12-31 | $369.97 Million | +442.63% |
| 2023-12-31 | $68.18 Million | -8.58% |
| 2022-12-31 | $74.58 Million | -- |
About Zenas BioPharma, Inc. Common Stock
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, an… Read more